Related Experiment Videos
Acute post-stroke adiponectin in relation to stroke severity, progression and 6 month functional outcome
Stella G Marousi1, Georgios L Theodorou, Marina Karakantza
1Department of Neurology, University Hospital of Patras, 26500 Rion-Patras, Greece. smarousi@upatras.gr
Neurological Research
|December 22, 2009
Summary
Higher levels of circulating adiponectin (ADPN) in acute ischemic stroke (IS) patients did not predict long-term outcomes. This study suggests ADPN may not be a reliable biomarker for stroke severity or prognosis in humans.
Area of Science:
- Neuroscience
- Cardiovascular Medicine
- Biomarker Research
Background:
- Circulating adiponectin (ADPN) exhibits anti-inflammatory and anti-atherosclerotic properties, linked to reduced risk of coronary artery disease and ischemic stroke (IS).
- Experimental studies suggest ADPN may offer cerebroprotection in brain ischemia, potentially influencing stroke outcomes.
- The role of acute post-stroke ADPN levels in human disease severity, progression, and outcome requires investigation.
Purpose of the Study:
- To investigate the association between acute post-stroke serum adiponectin (ADPN) levels and disease severity, progression, and functional outcomes in human ischemic stroke (IS) patients.
- To evaluate ADPN's predictive value for stroke severity, clinical progression, infarct size, mortality, recurrent IS, and mental state over a 6-month follow-up period.
Main Methods:
- Serum ADPN levels were measured in 82 consecutive acute IS patients.
- Stroke severity and progression were assessed using established definitions and scales, including the modified Rankin scale (mRS) and Barthel index (BI).
- Functional outcomes, infarct size, mortality, recurrent IS, and mental state were evaluated at 1, 3, and 6 months post-stroke.
Main Results:
- Higher ADPN levels correlated with greater disability (mRS) at 1 month (OR=1.141, p=0.031), but this was not confirmed by the Barthel index.
- ADPN levels were not significantly associated with stroke severity, clinical progression, infarct size, recurrent IS, mortality, or mental state.
- No association was found between acute ADPN levels and functional outcomes over the 6-month follow-up period.
Conclusions:
- Serum ADPN measured shortly after acute ischemic stroke in humans does not reliably predict disease severity, progression, or long-term outcome.
- Contrary to experimental findings, circulating ADPN may not beneficially modify the long-term outcome of acute ischemic stroke in humans.
- The predictive utility of ADPN as a biomarker for human stroke requires further investigation and may be limited.
